SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
FOR THE FISCAL YEAR ENDED COMMISSION FILE NUMBER
December 31, 2004 0-12248
Daxor Corporation
(Exact name of Registrant as specified in its charter)
New York 13-2682108
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification Number)
350 Fifth Avenue
Suite 7120
New York, New York 10118
(Address of principal executive offices) (Zip Code)
Registrant's telephone number: (212) 244-0555
Securities registered pursuant to Section 12(b) of the Act:
Common Shares, $.01 par value
(Title of Class)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether Registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months and (2) has been subject to such filing requirements for
the past 90 days.
Yes |X| No |_|
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-X is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
form 10-K. |_|
As of June 30, 2004, the aggregate market value of the voting stock held by
non-affiliates of the Registrant was $31,017,927. The market value of Common
Stock of the Registrant, par value $.01 per share, was computed by reference to
the closing price of one share on such date, as reported by the American Stock
Exchange, which was $21.55.
The number of shares outstanding of the Registrant's Common Stock, par value
$.01 per share, as of April 11, 2005: 4,637,326 shares.
DOCUMENTS INCORPARATED BY REFERENCE:
The information required by Part III is incorporated by reference from the proxy
statement for the 2005 Annual Meeting of Shareholders which will be filed with
the Securities and Exchange Commission within 120 days after the close of the
Registrant's 2004 year end.
DAXOR CORPORATION
FORM 10-K
For the Fiscal Year Ended December 31, 2004
TABLE OF CONTENTS
Item Description Page
- ---- ----------- ----
PART I
Item 1. Business 2
Item 2. Properties 11
Item 3. Legal Proceedings 12
Item 4. Submission of Matters to a Vote of Security Holders 12
PART II
Item 5. Market for Registrant's Common Equity and Related Shareholder 12
Matters
Item 6. Selected Financial Data 13
Item 7. Management's Discussion and Analysis if Financial Condition and
Results of Operations 14
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 16
Item 8. Consolidated Financial Statements 16
Index to Financial Statements 17
Item 9. Changes and Disagreements with Accountants on Accounting
and Financial Disclosure 18
Item 9A. Controls and Procedures 18
PART III
Item 10. Directors and Executive Officers of the Registrant 18
Item 11. Executive Compensation 18
Item 12. Security Ownership of Certain Beneficial Owners and Management
Related Shareholder Matters 18
Item 13. Certain Relationships and Related Transactions 18
Item 14. Principal Accountant Fees and Services 18
PART IV
Item 15. Exhibits, Financial Statement Index and Reports on Form 8-K 19
Signatures 20
Exhibit 31.1 Certification of Chief Executive Officer Pursuant to Rule 13a-14 of
the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
Exhibit 31.2 Certification of Chief Financial Officer Pursuant to Rule 13a-14 of
the Exchange Act, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
Exhibit 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
Exhibit 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
1
Item 1. Business
Daxor Corporation is a medical device manufacturing Company with additional
biotech services. Daxor was originally founded in 1970 for cryobanking services.
For the past 10 years, its major focus has been on the development of an
instrument that rapidly and accurately measures human blood volume. The
instrument, called the BVA-100(TM), is used in conjunction with a single use
radiopharmaceutical diagnostic injection and collection kit. The Company
maintains a website, www.daxor.com which describes its operations.
The Company obtained marketing clearance from the FDA for the instrument and for
its specialized single use injection kit known as Volumex(TM). After successful
beta testing for the Blood Volume Analyzer at hospitals in the New York
metropolitan region, the Company expanded marketing efforts outside of the New
York region. Test results from hospital sites indicated that the Blood Volume
Analyzer was accurate and provided information that was important in a wide
variety of acute and chronic medical and surgical situations. The Company
manufactures its own injection kit components. The Company established a small
scale manufacturing facility in Oak Ridge, Tennessee for research and
development purposes as well as for manufacturing the Blood Volume Analyzer. The
Blood Volume Analyzer is also manufactured for Daxor by an Original Equipment
Manufacturer (OEM). This combination provides flexibility to meet potential
increased market demand. The injection kit filling is performed by an FDA
licensed radiopharmaceutical manufacturer. The Company manufacturers a
specialized collection kit which is used in conjunction with the injection kit.
The Company has received United States, European Common Market, and Japanese
patents for its Blood Volume Analyzer.
Blood volume measurement has been available for more than 60 years in formats
that required as much as four to eight hours of technician time with variable
degrees of accuracy. Due to the time required, certain technical shortcuts were
often used which reduced the accuracy of the measurement. An additional problem
was the difficulty of calculating an accurate expected normal blood volume for a
specific individual. Normal blood volume has been shown to vary in relation to
the degree of deviation from ideal weight. A leaner individual has a higher
blood volume percentage of body weight as compared to an obese individual. The
computations for an individual's normal expected blood volume were complex and
time consuming. The BVA-100(TM) Blood Volume Analyzer automated these
computations. The BVA-100 Blood Volume Analyzer has an accuracy of approximately
98% while also providing the predicted normal blood volume for that specific
individual based on the height, weight and sex of the patient. In emergency
situations, preliminary results can be available within 20 to 25 minutes, and
final results within 30 to 45 minutes. The Company's patented injection and
collection kit, Volumex(TM), utilizes Albumin I-131 which is a classic tracer
used for blood volume measurement. The kit includes two matching standards along
with the pre-measured volumetric flow chamber which contains the
radiopharmaceutical. This kit, in conjunction with the Blood Volume Analyzer,
has resulted in the elimination of most of the multiple previous time consuming
steps whereby the institution needed to create their own standards.
Measurement of blood volume is achieved by the use of a radioisotope indicator
or tracer that is injected into a patient, and followed by the collection of
timed blood samples. The volume of blood in a patient is inversely proportional
to the dilution of the tracer. The measurement, while relatively simple in
principle, has been difficult to perform accurately and rapidly because of the
high degree of precision required in each step. The standard techniques require
the hospital or user to prepare an exact matching set of standards, with precise
and complete injection of the tracer. This is followed by the collection of 5
timed samples. Due to the difficulty in achieving this type of precision, blood
volume measurements are currently performed in only a small minority of
hospitals in the United States. The standard tests, the hemoglobin and the
hematocrit, used to diagnose anemia, measure only the thickness (percentage of
red cells to plasma within the blood) and not the volume of an individual's
blood. These surrogate or proxy tests are well known to be misleading in many
situations where blood volume is abnormal. In acute situations, such as during
surgical blood loss or after trauma, it may take as long as 24 to 72 hours for
the hematocrit to accurately or reasonably reflect the degree of blood loss. The
BVA analyzer, with its injection and collection system, for the first time,
makes blood volume measurement a practical clinical tool.
The following paragraphs describe some of the multiple conditions where a blood
volume measurement can make the difference between life and death.
Approximately 5 million individuals are treated annually for congestive heart
failure. It is estimated that $38 billion is spent annually on treatment for
congestive heart failure, of which $23 billion is spent annually on hospital
treatment of congestive heart failure patients. Congestive heart failure is the
number one reason for admission to hospitals in the US for patients over 65
years of age. Three thousand patients annually receive heart transplants. The
overwhelming majority of patients treated for heart failure must be treated with
a combination of powerful drugs which may drastically change the blood volume of
the patient.
Two major heart studies from the New York Presbyterian Medical Center and
Hospital were recently published in the leading cardiac journal Circulation. One
study involved the treatment of anemia in heart failure patients using the
BVA-100. The second study involved the effects of Erythropoietin on exercise
performance in anemic patients with congestive heart failure. These studies
demonstrated that many heart failure patients had a true anemia, a decrease in
red cell volume. In congestive heart failure the patients may accumulate extra
water, which expands their plasma volume. Physicians frequently assume that
these patients have their red cells diluted and are not truly anemic. These
studies demonstrated that many of these patients were truly anemic and could be
markedly improved by treatment with a drug such as Epogen which stimulates their
bone marrow to make more red blood cells. However, these studies demonstrated
that without a blood volume, physicians correctly diagnosed a patient's volume
derangement only 51% of the time. These were severely ill cardiac patients being
considered for cardiac transplants and/or ventricular devices. Several other
studies have recently confirmed that congestive heart failure patients who are
truly anemic may have very significant improvement without resorting to drastic
therapy such as a cardiac transplant. Cardiac transplants are obviously
available to only a very small fraction of congestive heart failure patients.
The ability to treat these patients medically has major implications with
respect to prolonging the lives of these patients. Senior authors were
Ana-Silvia Androne, MD; Stuart D. Katz, MD, et al; and Donna M. Mancini, MD;
respectively.
Dr. Stuart Katz and his colleagues at Columbia Presbyterian performed another
observational study on congestive heart failure patients using the Blood Volume
Analyzer. In an observational study, the cardiologists treated the patients
according to their usual clinical guidelines. Blood volume measurements were
obtained but were not incorporated into the treatment. The study lasted 2 years
and was published in the American Journal of Cardiology in May 2004. The study
reported that at the end of 1 year 39% of the patients who were Class III, Class
IV cardiac patients who were hypervolemic (excessive blood volume) were dead.
None of the patients who had normal blood volume or slightly reduced
blood volume had expired. At the end of 2 years, when the study was
discontinued, 55% of the hypervolemic group were dead, and none of the normo
volemic group had expired. One of the prime derangements in congestive heart
failure is the expansion of blood volume, particularly the plasma volume, which
may cause a patient to develop acute pulmonary congestion and may lead to sudden
death. Another important part of the study was an evaluation of how accurate
physicians who were trained in cardiology were in assessing a patient's blood
volume status using the standard laboratory tools and physical examination.
Faced with 3 possible choices, decreased, normal, or increased blood volume,
these physicians were correct only 51% of the time in evaluating the severely
ill cardiac patients. These remarkable studies were not funded or sponsored by
Daxor.
Currently physicians are forced to choose powerful medications which alter the
patient's blood volume without the correct knowledge of the patient's true blood
volume status. We believe that these landmark studies which document the
importance of correcting a cardiac failure patient's blood volume to normal,
including both their red cell volume and plasma volume status, can significantly
prolong their lives. Multiple case reports from other cardiologists on the use
of the Blood Volume Analyzer have confirmed that congestive heart failure
patients may have serious blood volume derangements that cannot be correctly
diagnosed without an actual blood volume measurement. Dr. Katz, who is currently
Associate Professor of Internal Medicine and Cardiology at Yale University
Medical Center at New Haven, authored additional published studies on blood
volume measurement on heart failure patients utilizing the BVA-100(TM).
Syncope, or sudden loss of consciousness, is a major cause for hospitalization
in the United States. As many as one million individuals per year experience an
episode of syncope. Patients who experience syncope may suffer severe injuries
when they collapse. Some patients may experience light-headedness without
complete loss of consciousness. Evaluation of such patients includes
neurological and cardiovascular testing, however, they do not usually include a
blood volume measurement. Low blood volume can be a predisposition to syncope.
Patients with this condition are frequently treated with different types of
drugs without precise knowledge of the underlying cause of the syncope.
The Cardiovascular Department of the Cleveland Clinic obtained a BVA-100(TM)
Blood Volume Analyzer in March 2000 for their Syncope Section. Results on over
one thousand patients in the Cleveland Clinic have demonstrated that a
significant percentage of such patients have moderate to severe hypovolemia (low
blood volume) which would not have been diagnosed without an actual blood volume
measurement. This scientific data has been submitted for publication in a
medical journal by Dr. Fetnat Fouad-Tarazi, Head of Hemodynamic and
Neuroregulation Lab, the Syncope Clinic, Department of Cardiology. The Cleveland
Clinic Cardiovascular Department is ranked number one in the United States
according to the annual US News & World Report survey of US Hospitals. The
hospital is ranked number 3 overall out of more than 6,200 hospitals in the
country. At the present time, most patients evaluated for syncope in hospitals
have tilt-table testing which identifies patients who may be at risk for
syncope. However, tilt-table testing does not differentiate patients who have
low blood volume from those who have neurological dysfunction of their blood
pressure. Only a blood volume measurement can provide this differential
diagnosis. The treatment for low blood volume involves medication to expand the
blood volume to normal. Neurological dysfunction involves different medical
treatment to control the low blood pressure. Blood volume measurement provides a
key test to facilitate correct treatment of patients.
A recent study by the Mayo Clinic estimated that there are 50 million Americans
who have hypertension (high blood pressure). It is reported that 70% of
hypertensive patients have their blood pressures inadequately controlled.
Hypertension is caused primarily by two variables. There is either a) excessive
blood (hypervolemia) or fluid retention within the circulation or b) excessive
tightening of the blood vessels (vasoconstriction). Diuretics are one major
category of drugs used to treat hypertension. Diuretics cause the kidney to
excrete salt and water thereby decreasing the blood volume and lowering the
blood pressure. A second major category of medications are vasodilators. These
drugs relax the blood vessels and lower the blood pressure. Within each of these
two major categories are drugs that work by different mechanisms, but they all
fall into one of these two main therapeutic categories, diuretics or
vasodilators.
Treatment is often a trial and error approach because neither vasoconstriction
nor blood volume is actually measured in a patient (with rare exception). One of
the most serious complications of hypertension is loss of kidney function (renal
failure) which may require a patient to undergo permanent renal dialysis.
Over the past year, the Company has received reports on patients treated for
hypertension with diuretics, who have a low blood volume. The physicians
treating these patients reduced or removed the diuretic therapy.
African-Americans have been reported to have significantly higher rates of
strokes and kidney failure as compared to Caucasians for comparable levels of
elevated blood pressure. Diuretic therapy is expected to benefit patients whose
elevated blood pressure is caused by an expanded blood volume. Diuretics may,
however, be harmful for patients whose high blood pressure is accompanied by low
blood volume. At the present time, there is inadequate data to determine whether
African- Americans, as a group, are more likely to be treated with diuretics.
The kidney is particularly vulnerable to low blood volume. It is well known that
certain medications, such as diuretics, can cause blood volume to decrease and
increase the possibility of kidney failure. The measurement of blood volume in
the treatment of hypertension may help prevent these types of complications. By
measuring the blood volume within the patient, the physician can make a more
rational or scientific choice in regard to the medical therapy to be
administered.
The New England Journal of Medicine and the Journal of the American Medical
Association (JAMA) recently published 2 large-scale studies concerning the use
of diuretics vs. vasodilators. One of the studies that encompassed thousands of
patients found that diuretics were better. The other study which also
encompassed thousands of patients came to the opposite conclusion.
Unfortunately, in neither of these studies was blood volume measured. Physicians
have been puzzled by these conflicting results. The Mayo clinic, which purchased
the BVA-100(TM), previously reported that blood volume measurements can be
helpful in defining therapy. If every patient with hypertension had at least one
blood volume performed in their lifetime to help define optimum therapy, this
would be a very cost-effective test. This is because of the high degree of
complications such as kidney failure which hypertensive patients experience.
Surgical patients who lose blood are particularly at risk for blood volume
derangements. Standard tests such as the hemoglobin or hematocrit which are used
to test for blood loss only measure the concentration (or percentage) of red
cells in the plasma in the blood. These tests do not measure the volume of
blood. It may take hours or even days before a patients' blood can be thinned
out to reflect the true amount of blood loss. Sometimes the first indication
that a patient with a relatively lower hematocrit has lost a large quantity of
blood is the collapse of the circulation. Sometimes physicians resort to the use
of Pulmonary Artery Catheterization (PAC). PAC involves the insertion of a
catheter into a vein through the right chamber of the heart and into the lung.
This has frequently been used as a surrogate technique to evaluate blood volume
in critically ill patients. However, PAC directly measures pressure, not volume.
The Lutheran Medical Center (New York) reported research on the first comparison
of PAC with direct blood volume measurements in patients. Their findings using
the BVA-100(TM) confirmed that PAC could be inaccurate and misleading in
patients who had significant blood volume deficits. Hypovolemia, or low blood
volume, can be particularly dangerous during surgery and may lead to sudden
severe drops in blood pressure. Such a drop in blood pressure, also known as
shock, is associated with strokes, heart attacks or even sudden death.
Researchers at Columbia Presbyterian will soon have a study published shortly on
patients with so-called diastolic heart failure utilizing the BVA-100(TM).
Diastolic heart failure is a major category in heart failure which is difficult
to treat. A blood volume measurement may provide essential information for
optimum treatment in these patients.
According to the Journal of Clinical Geriatrics, one out of every three elderly
patients has a condition known as orthostatic hypotension. Orthostatic
hypotension is a condition when a person rises from a sitting or reclining
position, the blood pressure drops.
This sudden drop in blood pressure may cause dizziness or even loss of
consciousness. One in eight elderly Americans experience a hip fracture. It is
unknown how many of these hip fractures are caused by patients having a
transient drop in blood pressure. A blood volume measurement can help
differentiate the cause of orthostatic hypotension. Some patients with low blood
volume caused by either low red cell volume or low plasma volume can be treated
with medications. Patients who have a normal blood volume with orthostatic
hypotension have a condition related to autonomic dysfunction or ineffective
control of the constriction of small blood vessels. A medication is available
for treating this condition.
Low red cell volume, or Anemia, is a common occurrence in patient's undergoing
chemotherapy for AIDS or cancer. Epogen and Procrit, which are manufactured by
the Amgen Corporation, can provide therapy for such conditions. Procrit is
distributed by the Ortho Division of Johnson & Johnson. The standard surrogate
tests, hematocrit and hemoglobin, may not reflect the full degree of decreased
red blood cell volume in such patients. A blood volume measurement can detect
unrecognized low blood volume or "hidden anemia" in such patients that may be
contributing to a profound feeling of weakness common in such conditions.
Chronic fatigue syndrome is a condition said to affect approximately one million
Americans, particularly patients with low blood pressure. Low blood volume has
been reported to be a factor in such conditions. The ability to measure blood
volume with a high degree of precision and accuracy may identify patients with
low blood volume who are not optimally treated at the present time.
There are over 4 million patients who receive blood transfusions every year. The
Company believes that if the BVA-100(TM) were available in every hospital, it
would be feasible for the hospital to routinely perform a blood volume test on
every patient for whom a blood transfusion appeared to be indicated. Several
manufacturers including Northfield Laboratories, Biopure, and Hemosol
Corporation are testing blood substitutes. To date, despite many attempts by
these companies, none of them have received FDA approval for these procedures.
These substitutes can be used for surgical procedures instead of donor
transfusions. These artificial blood substitutes have the advantage of a long
shelf life and the ability to be sterilized. They have the disadvantage of a
shortened half-life in the body after transfusion. None of the companies elected
to use a BVA-100(TM) in their studies. In these studies, patients were being
treated with a blood substitute without knowing what the patient's blood volume
was at the beginning of the transfusion and the patients' blood volume at the
end of the transfusion. This type of information can be readily available if the
BVA-100(TM) was used in studies involving blood substitutes. Lack of this type
of basic information may be one of the factors behind the FDA's unwillingness
over the past 10 years to license any of these types of hemoglobin substitutes.
There have been recent reports in the New England Journal of Medicine that as
many as 60% of patients undergoing Cardiac Bypass Surgery (CABG) experience some
degree of measurable permanent brain damage such as memory loss. Under current
transfusion practices, patients may undergo major surgery with half the
concentration of normal red cells. The practice of undertransfusion is
widespread. In the Journal Transfusion, Dr. Robert Valeri, a senior researcher
at the Boston Naval Hospital estimated that there may be as many as 40,000 heart
attacks per one million operations due to undertransfusions. The Company is
attempting to initiate a cooperative program which will involve the use of blood
volume measurement combined with the use of blood substitutes during surgery.
The Company believes that it can provide a significant advantage to companies
currently testing blood substitutes on patients without a precise knowledge of
the patient's actual blood volume. Patients who have low blood volume at the
start of surgery may respond very differently than a patient with a normal blood
volume who is treated with a blood substitute.
The current guidelines for the use of these products are based on hemoglobin and
hematocrit measurements. These tests, however, may be very misleading in regard
to the total amount of red cells a patient has in his/her body. A patient who
has a low blood volume that is undetected may have an artificially elevated
hematocrit. Such a patient may experience
severe fatigue and other symptoms that could be improved by appropriate
treatment. These patients have a form of "hidden anemia" and are not optimally
treated. It is only with the use of a blood volume measurement that the lower
red cell volume could be detected and treated. Blood volume measurement that
could detect low blood volume in patients with cancer, kidney disease, or heart
failure could significantly increase the justification and use of these blood
stimulants.
The Company is currently exploring the development of low blood volume detection
and treatment programs in conjunction with several hospitals. Many patients
undergoing elective surgery donate blood to themselves prior to that surgery.
Some patients have undetected low blood volume and should not be donating blood.
Undetected "hidden anemia" can be corrected if diagnosed prior to surgery by the
use of medications such as Epogen or Procrit. A woman has 16-18% less red cell
volume than a man of equal height and weight. Women suffer from a higher rate of
complications and require more transfusion during Cardiac Bypass surgery (CABG).
The use of low blood volume detection and treatment programs can result in a
significant improvement in patients at the time they are undergoing surgery.
Common complications from acute low blood volume are strokes, heart attacks, and
kidney failure.
Surgical patients who experience these complications require extended hospital
stays for which the hospitals are often not reimbursed. Hospitals operate under
a Diagnostic Regulatory Guideline (DRG) system for reimbursement. The DRG system
means that a hospital will be reimbursed according to a diagnosis, not according
to the number of days that a patient spends in the hospital.
Hospitals, however, have a significant monetary incentive aside from the desire
to provide better patient care, to avoid having patients undergo surgery in a
blood depleted state. A low blood volume detection and treatment program can
significantly improve the opportunity for patients to avoid complications from
hypovolemia as well as transfusions with donor blood. The Company believes that
the most significant market for its blood volume measurement equipment consists
of approximately 8,500 hospitals and Radiology Imaging Centers in the United
States.
The Company believes that there is an additional international market of 10 to
14,000 potential users of its BVA-100(TM). Blood volume measurement is an
approved test with six separate CPT codes. Reimbursement has been received from
a number of insurance companies, including Medicare for measurement of blood
volume using the BVA-100(TM). Reimbursement is particularly important for
hospitals because hospitals may receive additional reimbursement and income from
non-hospitalized patients who undergo blood volume measurement.
SCIENTIFIC MEDICAL SYSTEMS SUBSIDIARY (wholly owned by Daxor)
BLOOD BANKING
The Company's frozen blood bank is the only blood bank in New York that allows
people to store their own blood for up to ten years. In 1985, the Company
established the first facility in the United States for long-term autologous
(self-storage) blood banking. The blood banking industry is a group of
for-profit and not-for-profit corporations whose total revenue is estimated to
exceed six billion dollars.
Utilizing cryobiology technology, frozen blood has been shown to be capable of
being stored for up to 37 years, however, the current legal limit is 10 years
for red cells. The present donor system of blood transfusions presents risks to
those individuals receiving blood. This is a risk that can be avoided by
utilizing one's previously stored blood. There are approximately 15-18 million
blood transfusions administered annually to 4 million patients. Despite improved
testing, significant risks still remain from diseases such as West Nile Virus,
which can be transmitted by transfusion. Diseases such as
Hepatitis and HIV can also be transmitted by infected donors who may test
negative for up to 6 months after the initial infection. The FDA is particularly
cautious and will not permit an individual who received a transfusion to donate
blood to another person for a period up to 1 year after receiving the
transfusion. This regulation is designed to exclude donors who may be infected
but undetectable by the standard tests used for screening donors.
The risks of infection and other complications are compounded by the frequent
withholding of blood from severely anemic patients by their physicians because
of the known risks of transfusion. It is a common medical practice to replace
the first three pints of lost blood with three pints of sterile water or their
equivalent. This problem has not been brought to the public's attention, but it
is widely known among physicians who have treated patients who have lost blood.
The number of patient's who suffer major complications, including sudden death
from under-transfusion, is unknown but significant. The Blood Volume Analyzer
has the potential to detect such individuals before complications from
under-transfusion occurs. Physicians who fear the complications of transfusion
with potentially contaminated blood do not have these concerns when patients use
autologous blood (self-storage).
The Company believes that an educational process can establish the advantages of
autologous blood storage. Education can also overcome opposition to any change
in the current blood banking system from established tax-exempt (non-profit) and
profit-making entities. The Company believes that it can work with some
voluntary blood banks and hospitals to establish joint marketing of long term
frozen personal blood storage programs.
Blood Banking services are provided by a broad spectrum of organizations.
Approximately one-half of the blood supply used for transfusions, are supplied
by the American Red Cross and its affiliates. The other portion is supplied by
various other tax-exempt and for-profit organizations. Some hospitals operate
their own donor services, but require the services of outside vendors such as
the Red Cross for adequate supplies of blood products. At the present time there
are no other organizations providing long-term personal frozen blood storage in
the Northeastern United States. It is the Company's intentions to form alliances
with other short-term donor blood banks to expand frozen personal blood storage
services.
The Company views personal blood storage as a supplement to and not as
competition to other existing blood donor services.
Idant (Division of Scientific Medical Systems, a wholly owned subsidiary of
Daxor Corporation) Semen (Sperm) Banking
In 1985, Idant was the first semen bank to institute an AIDS quarantine period
for frozen semen. Viruses such as HIV and Hepatitis B or C may be undetectable
for up to six months in infected individuals. By freezing the semen of donors
and re-testing the donor six months later, the risk of Hepatitis or AIDS can be
virtually eliminated. In 1989, New York State and a number of other states
enacted laws requiring sperm banks to freeze and quarantine sperm for a minimum
of six months. The donors are tested at the beginning and at the end of the
six-month period. By storing semen from a large cross-section of donors, Idant
is able to offer anonymous donor semen with varying physical characteristics
that meet our client's needs. The Company maintains a complete physical
description of each donor on file and matches multiple physical characteristics
and additional special characteristics sought by the family to those of the
sterile father. The Company also provides, on request, special screening for
rare hereditary recessive genetic traits. The increased likelihood of a child
who resembles his recipient father can make the child, who is conceived via
artificial insemination, much more psychologically acceptable to the father.
Storage of Sperm for Personal Use
Idant pioneered both the technology and the commercial application of long-term
preservation of human sperm for use in artificial insemination. The division has
provided frozen semen services to physicians worldwide. Idant holds
approximately 50,000 human semen units in long-term storage at its central New
York City facility. The Company was the first semen bank in the state of New
York, out of more than 50 licensed banks, to be accredited by the American
Association of Tissue Banks. Idant provides semen storage services for clients
which remain viable for many years. Semen stored for 30 years, at minus 321
degrees, has shown minimal change.
In 2004 Idant received confirmation of the longest successful conception in
medical history from frozensperm stored at Idant for respectively 21 years for 1
birth, and 29 years for a second birth. Idant has submitted this information to
a major journal dealing with fertility and will publicize this news upon
acceptance for publication. The Company believes that its unique storage system
for human sperm is responsible for this extraordinary success. The pregnancies
were notable because they were achieved by artificial insemination. The previous
record was for 20 years and was achieved by the considerably more expensive in
vitro fertilization method. The Company is aware of only one other semen bank,
which uses the carousel system for long-term storage of semen The Company's
facility is used by men who, for a variety of reasons, anticipate impairment of
their ability to father children and by men who have been found to be marginally
fertile. These men may now be able to have children by use of techniques that
increase their fertility by treating their sperm to artificially inseminate
their partners. The facility is also used by men who plan to undergo
sterilization by vasectomy, but who believe that they might desire children in
the future. Artificial insemination using stored sperm is much more effective
and less expensive than present techniques of vasectomy reversal. In addition,
patients with a variety of diseases, including many types of cancer, store semen
prior to undergoing treatment by chemotherapy or radiation. By utilizing
cryogenic preservation facilities, these patients, who are frequently in their
teens or twenties, will be able to father their own children after cancer
treatment, despite the high risk of sterility and birth defects associated with
treatments. The Company receives referrals for these services from multiple
sources, primarily physicians.
The Company uses a customized carousel canister system in its sperm bank storage
system. This permits retrieval of specimens from lower levels without removal of
upper specimens. Only a few other sperm banks in the U.S. are known to have such
a system.
Most other banks use a "rack and cane" pull-up system, which requires removal of
upper specimens from the tank to retrieve specimens at lower levels. In such a
bank, a specimen may be exposed to a temperature change of -321oF (the
temperature of the liquid nitrogen) to room temperature of 72oF more than 100
times during its storage lifetime. This will result in a gradual degradation of
the specimen. In the Idant system the specimen remains under liquid nitrogen
almost continuously while in storage. We believe that this specialized system is
the reason for the longest interval for frozen sperm storage and successful
conception.
Patent and Copyright Protection
The Company has received separate United States patents on its Blood Volume
Analyzer BVA-100(TM) and for its Volumex(TM) injection kit. These are the only
US patents ever issued for an instrument dedicated to the measurement of total
human blood volume for a specific individual. The Company received a European
patent covering 12 countries. The Company received the first patent ever issued
for an instrument in Japan to measure human blood volume. The instrument is
designed to work with an injection kit manufactured by the Company. It is
theoretically possible to use the Blood Volume Analyzer without the kit by
preparing the reagents used for the test. However, the cost and time for such
preparations would be uneconomical and it is unlikely that a purchaser of the
instrument would use it without purchasing the reagent kit. This is the first
U.S. patent ever issued for a system, which permits a fixed quantitative amount
of
isotope to be injected for diagnostic purposes. The injection system was
specifically designed for use with the BVA-100(TM). However, it can be used for
other diagnostic test purposes where a precise complete quantitative injection
of a diagnostic reagent is required.
The Company expects to file additional patents for tests associated with the
BVA-100. These include filing a patent for equipment which will automate the
measurement of glomerular filtration rate of the kidney. This is a very
important and sensitive test of kidney function. At the present time this test
is infrequently performed because of the difficulty in the current methodology.
The Company believes that it can automate this process which will make it more
feasible for regular medical use.
A patent will be filed for the measurement of total body albumin. Albumin is a
major carrier of hundreds of vital components within the circulation. Albumin
derangement is common in many disease states. Burn patients in particular have
serious loss of albumin, and replacement quantities may be difficult to
calculate. Patients with congestive heart and with cancer and diabetes failure
also frequently have albumin derangements. The ability to measure total body
albumin accurately would be expected to facilitate more precise therapy.
The Company has developed a Blood Optimization Program (BOP). The Company has
applied for trademark protection and is in the process of applying for a methods
patent for the concept. The underlying principal is to enable patients
undergoing elective surgery to store frozen blood in advance of surgery at a
frequency which will be determined in conjunction with blood volume measurement.
Patients who store blood just prior to surgery are frequently anemic and are at
a higher risk for complications as compared to the risk which they would face if
they had not donated blood just prior to surgery. Instead, utilization of frozen
blood stored well in advance of surgery enables a patient to undergo surgery
with a normal amount of blood instead of in an anemic state.
The Company is also exploring the submission of a patent for methodology of
improving client identification in its semen bank. It is introducing additional
patient protection for stored donor semen which may be eligible for patent
protection. In the 33 years of the Bank's operations, it has never had a mix-up
in any stored specimen.
Marketing
In September 2002, the Company hired a National Sales Manager and 3 other
Regional Sales Managers with extensive experience in the medical device and
nuclear medicine field. Subsequently, several different sales models were
tested. It was determined that the best model was a National Sales Manager with
regional sales representatives. John Reyes-Guerra, one of the original regional
vice presidents was made Vice President of Sales and Marketing. The sales staff
was expanded to 12 sales personnel plus 6 support personnel. As part of the
support system, some sales representatives are hired to contact all physicians
in the regions and to assist in marketing efforts. They work in conjunction with
the equipment sales staff, and are developing the foundations for an in depth
marketing program utilizing the results from major teaching hospitals. The
Company believes that this is the appropriate time to continue expanding
marketing and sales efforts. These marketing representatives are paid on the
basis of increased kit utilization in their region. Their function is to assist
in educating physicians utilizing published research reports utilizing the blood
volume analyzer. The Company has also hired an additional staff member to handle
blood banking marketing services.
The Company is marketing its Blood Volume Analyzer either on a direct sale,
lease, or an instrument loaner basis to potential users. Primarily, users are
expected to be hospitals, surgi-centers, and imaging centers (radiology). The
Company also has been demonstrating its equipment at major trade shows such as
Nuclear Medicine, Surgical Anesthesiology, and trauma conferences. The Company
recognized after the initial beta testing that it was important to have the
Blood Volume Analyzer at leading medical institutions. Publications and reports
from such institutions are particularly important for acceptance by the general
medical community. During the past 2 years, a number of leading facilities
acquired a Blood Volume Analyzer. The US News and World Report provides an
annual ranking of 6200 Hospitals in the United States. The Mayo Clinic, and The
Cleveland Clinic, ranked respectively 2 and 3 in the annual ranking of hospitals
have a BVA-100(TM). The Cleveland Clinic Cardiovascular Department ranked number
1 in the US will soon be reporting on over 1000 patients on who blood volume
testing was performed. In addition to these facilities, Vanderbilt Medical
Center, and the New York Hospital Presbyterian Medical Center ranked in the top
20 in the Annual Survey of Hospitals also have a Blood Volume analyzer. The
National Institutes of Health, the leading US government research agency, has
acquired a Blood Volume Analyzer.
Hospitals and health facilities are exceedingly cost conscious in regard to
acquiring additional medical technology. Blood volume measurement is an approved
and reimbursable Medicare test. The Company expends great time and effort to
ensure that insurance companies reimburse hospitals correctly for the cost of
the radiopharmaceutical kit as well as for the performance of the test. There
are staff available to assist hospitals and physicians to utilize correct codes
and indications for blood volume measurement.
The Company's marketing efforts are focused on documenting the beneficial
effects of blood volume measurement as well as developing cost benefit analysis
studies. Such studies are particularly important to HMO's which focus on
avoiding hospitalization when possible. As these studies become available, they
will be incorporated into the marketing program of the Company.
The Company's website (http:// www.daxor.com) contains extensive detail about
the BVA-100(TM) Blood Volume Analyzer as well as examples of actual cases (with
patient identities removed). The website permits rapid communication between
marketing personnel and potential users prior to an onsite visit.
Competition
Blood Volume Analyzer
The medical technology market is intensely competitive. However, there are no
direct competing instruments manufactured or marketed that perform rapid,
accurate semi-automated blood volume analysis, such as the BVA-100(TM). The
Company believes that its receipt of a United States, European and Japanese
patent for its Blood Volume Analyzer provides significant protection against any
future potential competition in the blood volume analysis field.
The receipt of the U.S. patent for the injection kit system provides significant
additional protection as the Company believes that the kits will be a major
source of revenue. The Company believes that its main hindrance to market
acceptability will be the need to demonstrate that its blood volume measurement
equipment is capable of producing accurate data on a cost effective basis. Test
kit costs are modest relative to the cost of the critical information derived
from the test. The Company expects to file additional patents in regards to the
blood volume analyzer when it incorporates the measurement of total body albumin
into the analytic system.
Blood Banking
The Idant frozen blood bank is the only facility that provides long-term
personal frozen blood storage in the Northeastern United States. Multiple
companies which previously attempted to provide long-term personal blood storage
to members of the
public were unsuccessful. To date, the Company has not made a profit from its
blood banking services. The Company believes however that additional technology
which enables longer use of frozen blood after it is thawed for use may enable
such services to eventually becomes self-sustaining financially, and profitable.
The Company is in the process of developing programs whereby corporations can
provide frozen long term storage as a benefit to their employees. If the Company
receives a methods patent on its Blood Optimization Program, it will expand its
marketing personnel.
Semen Banking
There are at least 300 sperm banks in the United States operated by either
commercial entities or by academic institutions. The Idant semen bank was the
first semen bank in the State of New York that was accredited by the American
Association of Tissue Banks. There are less than 9 semen banking organizations
in the United States that have achieved this accreditation.
The Company believes that its unique storage system, coupled with clear
documentation of a successful conception occurring from the longest term for
frozen stored semen in medical history, will help it in expanding its marketing
efforts.
The Company has developed a web site (http: // www.Idant.com), which will be
helpful for marketing purposes.
Regulation
The development, testing, production and marketing of medical devices is subject
to regulation by the FDA under the Federal Food, Drug and Cosmetic Act, and may
be subject to regulation by similar agencies in various states and foreign
countries.
The governing statutes and regulations generally require manufacturers to comply
with regulatory requirements designed to assure the safety and effectiveness of
medical devices. The FDA clearance for marketing of the Blood Volume Analyzer,
BVA-100(TM), and the associated quantitative injection kit marks one of the most
important milestones in the history of Daxor. The products manufactured by and
for the Company in regard to the BVA-100(TM) are subject to continuing FDA
regulations and inspections.
The New York State Department of Health regulates the Company's Idant semen and
blood bank within New York State. The Idant Semen Bank and Blood Bank are
divisions of Scientific Medical Systems, which is a subsidiary wholly owned by
the Daxor Corporation. Scientific Medical Systems has its own separate
directors. These facilities are licensed and annually inspected by the New York
State Department of Health.
Labor Force
On March 24, 2005, the Company had a labor force of 46, all of which were leased
through ADP TotalSource. The Company believes that its labor force relations are
good.
Item 2. Properties
In December 2002, the Company signed a new thirteen-year lease for its existing
facility at the Empire State Building. The Company has occupied this space since
January 1992. The company currently occupies approximately 7,500 square feet.
The lease has a two year option for renewal after ten years. There are options
for an additional 18,000 square feet of space. The Company has a manufacturing
facility in Oak Ridge, Tennessee which is currently manufacturing the
BVA-100(TM) Blood Volume Analyzers. The Company also signed a contract with an
Original Equipment Manufacturer (OEM) for manufacturing the BVA-100. The
Company's Volumex syringes are filled by an FDA licensed radiopharmaceutical
manufacturer under contract with Daxor.
Item 3. Legal Proceedings
The Company had a suit which was filed in 2004 and dismissed in 2005.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of the Company's shareholders during the
fourth quarter of 2004.
Part II.
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters
The common stock is traded on the American Stock Exchange under the symbol DXR.
2004 High Low
---- ---
First Quarter $14.80 $13.95
Second Quarter $21.85 $14.37
Third Quarter $24.00 $19.00
Fourth Quarter $24.60 $20.25
High Low
---- ---
2003
First Quarter $16.15 $13.86
Second Quarter $16.25 $11.60
Third Quarter $17.65 $14.50
Fourth Quarter $15.40 $13.50
On March 31, 2005, the Company had approximately 192 holders of record of the
Common Stock. The Company believes there are approximately 1,500 beneficial
holders.
The Company paid a single cash dividend, $.50, on the Common Stock in 1997. Any
future dividends will be dependent upon the Company's earnings, financial
condition and other relevant factors.
ITEM 6. SELECTED FINANCIAL DATA
The following table sets forth certain selected financial data with
respect to the Company and is qualified in its entirety by reference to the
financial statements and notes thereto, from which these data were derived,
included elsewhere in the report.
Selected Statements of
Operations Data:
Year Ended December 31,
2004 2003 2002 2001 2000
---- ---- ---- ---- ----
Operating revenues $ 1,218,406 $ 1,013,647 $ 767,608 $ 591,692 $ 635,868
Dividend income 1,990,669 1,897,669 1,858,025 1,860,289 1,842,583
Gains on sale of investments 989,599 238,550 40,610 97,719 57,399
Other revenues 31,967 15,571 35,694 166,676 109,920
----------- ----------- ----------- ---------- -----------
Total revenues 4,230,641 3,165,437 2,701,937 2,716,376 2,645,770
----------- ----------- ----------- ---------- -----------
Costs and expenses:
Operations of laboratories
& costs of production 1,241,589 1,489,264 805,985 814,657 1,052,000
Selling, general and
administrative 3,460,370 2,669,229 2,050,546 1,482,438 1,450,623
Interest expense, net 108,950 83,133 39,257 119,926 198,341
----------- ----------- ----------- ---------- -----------
Total costs and expenses 4,810,909 4,241,626 2,895,788 2,417,021 2,700,964
----------- ----------- ----------- ---------- -----------
Loss before income taxes (580,268) (1,076,189) (193,851) 299,355 (55,194)
Provision for income taxes -- -- -- -- --
----------- ----------- ----------- ---------- -----------
Net income/(loss) $ (580,268) $(1,076,189) $ (193,851) $ 299,355 $ (55,194)
=========== =========== =========== ========== ===========
Weighted average number of
common shares outstanding
- basic and diluted 4,615,159 4,645,700 4,662,947 4,664,909 4,675,826
----------- ----------- ----------- ---------- -----------
Income (loss) per common
equivalent share - basic
and diluted $ (0.13) $ (0.23) $ (0.04) $ 0.06 $ (0.01)
=========== =========== =========== ========== ===========
Selected Balance Sheet Data:
Year Ended December 31,
2004 2003 2002 2001 2000
---- ---- ---- ---- ----
Working capital 39,558,589 36,044,529 33,136,421 34,979,217 38,309,247
Total assets 55,929,480 48,300,532 41,573,565 43,540,153 49,575,118
Total liabilities* 16,048,161 11,883,362 8,026,668 8,211,186 10,903,280
Stockholders' equity 39,881,319 36,417,170 33,546,897 35,328,967 38,671,838
Return on equity** (1.73%) (3.21%) (0.55%) 0.77% (0.19%)
* Total liabilities include deferred taxes on unrealized gains.
** Return on equity is calculated by dividing the Company's net income or
loss for the period by the stockholders' equity at the beginning of the
period.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
Idant Laboratories subsidiary contributed 48.5%, 45%,and 58% of operating
revenues in 2004, 2004 and 2002 respectively. The Company's operations in semen
banking and blood banking (laboratories) have received limited promotion;
however, the Company has taken steps to increase awareness of these services.
The potential market for the Blood Volume Analyzer is significantly larger than
the Company's current operations. The Company anticipates that proceeds from
Daxor's Blood Volume Analyzer will be the primary source of revenue in the
immediate future. The Company believes that the potential market for blood
volume measurement and analysis is between 15-20 million tests per year.
Successful penetration of even a small fraction of the market would
significantly change the Company's structure. The Company intends to focus its
major marketing efforts on the Blood Volume Analyzer.
During fiscal years 2004 and 2003, Daxor continued to expand its sales and
marketing staff. The Company intends to increase its marketing efforts to add to
its operational income. Some of the steps the Company had undertaken, such as
consolidating certain manufacturing facilities at Oak Ridge, Tennessee and
simultaneously contracting with an Original Equipment Manufacturer (OEM) will
permit greater economies of scale. The Company's primary focus will be to
increase operating revenues even if this initially results in lower profits or
even a loss.
YEAR ENDED DECEMBER 31, 2004 AS COMPARED TO DECEMBER 31, 2003
In 2004 revenue from operations was $1,218,406, with expenses from operations
totaling $4,701,959; the loss from operations was $3,483,553. Dividend income
earned on the Company's securities portfolio was $1,990,669 an increase from the
$1,897,669 reported in 2003. Gains on the sale of investments were $989,599 in
2004 as compared to $238,550 in 2003. In 2003 revenue from operations was
$1,013,647 with expenses from operations totaling $4,158,493; the loss from
operations was $3,144,846. The increase in operating costs was primarily due to
increased hiring of personnel and additional marketing and selling expenses
related to the Blood Volume Analyzer. The company anticipated these increased
operating expenses and intends to continue expanding its marketing and sales
staff. There was a net loss of $(580,268) in 2004 vs. a loss of ($1,076,189) in
2003. In 2004, the Company's total assets were $55,929,480 with loans
(short-term) totaling $4,113,285, and total debt of $16,048,161. The Company's
asset to debt ratio is 3.49:1.
YEAR ENDED DECEMBER 31, 2003 AS COMPARED TO DECEMBER 31, 2002
Total revenue from all sources was $3,165,437 in 2003, up from $2,701,937
reported in 2002. Dividend income earned on the Company's securities portfolio
was $ 1,897,669 an increase from the $1,858,025 reported in 2002. Gains on the
sale of investments were $238,550 in 2003 as compared to $40,610 in 2002.
Operating revenues increased to $1,013,647 in 2003 from $767,608 in 2002. Total
operating expenses increased to $4,158,493 in 2003 from $2,856,531 in 2002. This
increase was partially caused by increased hiring of personnel and additional
marketing and selling expenses. There was a net loss of ($1,076,189) in 2003 vs.
($193,851) in 2002.
LIQUIDITY AND CAPITAL RESOURCES
The Company's management has pursued a policy of maintaining sufficient
liquidity and capital resources in order to assure continued availability of
necessary funds for the viability and projected growth of all ongoing projects.
The Company continues to maintain its diversified securities portfolio comprised
primarily of electric utility preferred and common stocks. The income derived
from these investments has been essential to offset the research, operating and
marketing expenses of developing the Blood Volume Analyzer. The Company has
followed a conservative policy of assuring adequate liquidity so that it can
expand its marketing and research development without the sudden necessity of
raising additional capital. The securities in the Company's portfolio are
selected to provide stability of both income and capital. The Company has been
able to achieve financial stability because of these returns, which covered a
significant portion of the Company's continuing losses from operations.
At December 31, 2004, the Company had $16,048,161 in short-term debt vs.
$11,883,362 in 2003. At year-end 2004, stockholders' equity was $39,881,319. At
year-end 2003, the Company had stockholders' equity of $36,417,170. At December
31, 2004 the Company's security portfolio had a market value of $54,806,400 vs.
$47,399,159 in 2003. In 2003, the Company had sales staff of 4 and support
personnel of 3. The Company has expanded to 11 sales staff and support personnel
of 4 in 2004. Income from the Company's security portfolio is a major asset for
the Company as it expands its marketing staff.
The Company offers to lease or rent, as well as sell its Blood Volume Analyzer
BVA-100(TM) as part of an overall marketing plan. The Company established a
relationship with De Lage Landen from the Netherlands which is one of the
largest private banks in the world. De Lage Landen has extensive experience in
capital equipment leasing through its existing relationships with premier
corporations such as Toshiba and Abbott. The significance of this relationship
is as sales through leases increases, Daxor will not have to diminish its
capital outlay for equipment as DLL will fund the net
present value of the lease upon installation of the equipment. The Company will
also work with independent leasing firms. As part of its marketing program, the
Company will loan, an instrument for a limited time period and facilities
evaluating the instrument must pay for the kits.
The Company is also developing a blood volume laboratory staffing program with
one of its clients. Under such program, the Company may provide management
services as well as equipment services. With respect to blood banking, recent
technological advances have significant potential in proving the safety of blood
banking. A major handicap for the use of frozen blood was the fact that after it
was thawed, the blood had to be used within 24 hours. New technology approved by
the FDA and utilized by the U.S. military, enables blood to be used for up to 2
weeks after it has been thawed. The Company, in addition to its regular frozen
blood banking services, intends to implement this type of program. This type of
program will initially produce a net loss, but the Company believes that there
is sufficient potential demand that such a program will be self sustaining.
Year-end 2004 finds the Company in a satisfactory financial position with
adequate funds available for its immediate and anticipated needs. The Company
plans its budgetary outlays on the assumption that the raising of additional
financial capital may be difficult in the next 2 to 4 years. The Company
believes that its present liquidity and assets are adequate to sustain the
additional expenses associated with an expanding sales and marketing program.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
The Company is currently not exposed to any risk from currency fluctuations. The
Company's investment portfolio is a major source of revenue. A summary of the
status of this portfolio as of December 31, 2004 is reported in the financial
statement footnotes portion of this filing. The market value of this portfolio
is related to fluctuations with the electric utility industry. Between 5% and
10% of the holdings are non-utilities. The Company will sell puts on stocks that
it is willing to own. The Company does not sell naked calls nor engage in
derivative transactions. Fluctuations in the value of these holdings for the
past 5 years are reflected and closely correlated with changes in the total
assets (see item 6: selected financial data).
Item 8. Consolidated Financial Statements
Index to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
Report of Independent Auditors
Consolidated Balance Sheets - December 31, 2004 and 2003
Consolidated Statements of Operations for the years ended December 31, 2004,
2003 and 2002
Consolidated Statements of Stockholders' Equity and Comprehensive
Income for the years ended December 31, 2004, 2003 and 2002
Consolidated Statements of Cash Flows for the years ended December 31, 2004,
2003 and 2002.
Notes to Consolidated Financial Statements
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Daxor Corporation:
We have audited the accompanying consolidated balance sheet of Daxor Corporation
and Subsidiary (the "Company") as of December 31, 2004 and 2003, and the related
consolidated statements of operations, stockholders' equity and comprehensive
income, and cash flows for the year then ended. These consolidated financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audit. The financial statements of the Company as of
December 31, 2002 and for the year then ended, were audited by other auditors
whose report dated March 23, 2003 expressed an unqualified opinion on those
statements.
We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States of America). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of the Company as of
December 31, 2004 and 2003, and the results of its operations and cash flows for
the two years then ended, in conformity with accounting principles generally
accepted in the United States of America.
Rotenberg Meril Solomon Bertiger & Guttilla, P.C.
Saddle Brook, New Jersey
April 6, 2005
INDEPENDENT AUDITOR'S REPORT
To the Board of Directors and Shareholders of Daxor Corporation:
We have audited the accompanying consolidated balance sheets of Daxor
Corporation as at December 31, 2002 and the related consolidated statements of
income, shareholders' equity and comprehensive income, and cash flows for the
year then ended.
These financial statements are the responsibility of the Corporation's
management. Our responsibility is to express an opinion on these financial
statements and based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of Daxor Corporation as at December 31, 2002,
and the results of their operations and its cash flows for the year then ended
in conformity with generally accepted accounting principles.
Frederick A. Kaden & Co.
Brentwood, New York
March 24, 2003
DAXOR CORPORATION
CONSOLIDATED FINANCIAL STATEMENTS
================================================================================
DAXOR CORPORATION
CONSOLIDATED BALANCE SHEETS
December 31, December 31,
2004 2003
------------ ------------
- ------------------------------------------------------------------------------------
ASSETS
- ------------------------------------------------------------------------------------
CURRENT ASSETS
Cash and cash equivalents $ 5,079 $ 3,324
Available-for-sale securities 54,806,400 47,399,159
Accounts receivable 202,649 137,008
Inventory 139,338 146,185
Prepaid expenses and other current assets 453,284 242,215
------------ ------------
Total Current Assets 55,606,750 47,927,891
Property and equipment, net 290,572 303,373
Other Assets 32,158 69,268
------------ ------------
Total Assets $ 55,929,480 $ 48,300,532
============ ============
- ------------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
- ------------------------------------------------------------------------------------
CURRENT LIABILITIES
Accounts payable and accrued liabilities $ 89,162 $ 183,052
Loans payable 4,113,285 2,502,106
Other liabilities 982,718 667,123
Deferred revenue 17,465 --
Deferred taxes 10,845,531 8,531,081
------------ ------------
Total Current Liabilities and Total Liabilities 16,048,161 11,883,362
STOCKHOLDERS' EQUITY
Common stock, $.01 par value
Authorized - 10,000,000 shares
Issued - 5,309,750 shares
Outstanding - 4,610,826 and 4,639,026
shares, respectively 53,097 53,097
Additional paid in capital 9,821,563 9,801,548
Accumulated other comprehensive income 21,053,089 16,560,334
Retained earnings 14,589,699 15,169,967
Treasury stock, at cost, 698,924 and 670,724
shares, respectively (5,636,129) (5,167,776)
------------ ------------
Total Stockholders' Equity 39,881,319 36,417,170
------------ ------------
Total Liabilities and Stockholders' Equity $ 55,929,480 $ 48,300,532
============ ============
See accompanying notes to consolidated financial statements.
DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Year Ended December 31,
-----------------------
2004 2003 2002
---- ---- ----
Revenues:
Operating revenues $ 1,218,406 $ 1,013,647 $ 767,608
Operating expenses:
Operations of laboratories & costs of production 1,241,589 1,489,264 805,985
Selling, general, and administrative 3,460,370 2,669,229 2,050,546
Total Operating Expenses 4,701,959 4,158,493 2,856,531
Loss from operations (3,483,553) (3,144,846) (2,088,923)
Other income (expenses):
Dividend income 1,990,669 1,897,669 1,858,025
Gain on sale of securities 989,599 238,550 40,610
Other revenues 31,967 15,571 35,694
Interest expense, net of interest income (108,950) (83,133) (39,257)
----------- ----------- -----------
Total Other Income 2,903,285 2,068,657 1,895,072
----------- ----------- -----------
Loss before Income Taxes (580,268) (1,076,189) (193,851)
Provision for income taxes -- -- --
----------- ----------- -----------
Net Loss $ (580,268) $(1,076,189) $ (193,851)
=========== =========== ===========
Weighted Average Number of Shares
Outstanding - basic and diluted 4,615,159 4,645,700 4,662,947
----------- ----------- -----------
Loss per Common Share - basic and diluted $ (0.13) $ (0.23) $ (0.04)
=========== =========== ===========
See accompanying notes to consolidated financial statements.
DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year ended December 31,
2004 2003 2002
---- ---- ----
Cash flows from operating activities:
Net loss $ (580,268) $(1,076,189) $ (193,851)
----------- ----------- -----------
Adjustments to reconcile net loss
to net cash used in operating activities:
Depreciation and amortization 72,542 47,189 54,453
Gain on sale of investments (989,599) (238,550) (40,610)
Loss on sale of equipment -- -- (2,750)
Change in operating assets and liabilities:
(Increase) decrease in accounts receivable (65,641) 74,971 (37,737)
(Increase) decrease in inventory 6,847 3,040 (48,477)
Increase in other current assets (211,069) (26,527) (4,126)
Decrease in other assets, net of amortization 8,332 -- (300)
Increase (decrease) in accounts payable, accrued
expenses and other liabilities net of "short sales" (88,990) 66,471 60,626
Increase in deferred revenue 17,465 -- --
Total adjustments (1,250,113) (73,406) (18,921)
----------- ----------- -----------
Net cash used in operating activities (1,830,381) (1,149,595) (212,772)
----------- ----------- -----------
Cash flows from investing activities:
Purchase of property and equipment (30,963) (54,354) (114,879)
Proceeds from sale of equipment, net -- 45,000 2,750
Purchase of marketable securities, net (273,903) (340,893) (517,207)
Net proceeds from loans from
brokers used to purchase securities 1,011,179 868,060 734,046
Proceeds from "short sales" not closed 974,161 663,466 98,683
----------- ----------- -----------
Net cash provided by investing activities 1,680,474 1,181,279 203,393
----------- ----------- -----------
Cash flows from financing activities
Proceeds from (repayments of) bank loan, net 600,000 200,000 (300,000)
Proceeds from sale of treasury stock 25,997 30,736 --
Purchase of treasury stock (474,335) (272,131) (109,535)
----------- ----------- -----------
Net cash provided by (used in) financing activities 151,662 (41,395) (409,535)
----------- ----------- -----------
Net increase (decrease) in cash and
cash equivalents 1,755 (9,711) (418,914)
Cash and cash equivalents at beginning of year 3,324 13,035 431,949
----------- ----------- -----------
Cash and cash equivalents at end of year $ 5,079 $ 3,324 $ 13,035
=========== =========== ===========
Non-cash investing activities:
Unrealized gain (loss) on securities, net of deferred taxes $ 4,492,755 $ 4,187,857 $(1,478,684)
=========== =========== ===========
Supplemental cash flow disclosure:
Interest paid $ 111,745 $ 86,675 $ 40,533
=========== =========== ===========
See accompanying notes to consolidated financial statements.
DAXOR CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
--------------------
Common Stock Accumulated
-------------------- Additional Other Total
Number Paid In Comprehensive Retained Treasury Stockholders'
of Shares Amount Capital Income Earnings Stock Equity
-------------------------------------------------------------------------------------------------
Balances, December 31, 2001 4,663,909 $ 53,097 $ 9,798,232 $ 13,851,161 $ 16,440,007 $(4,813,530) $ 35,328,967
Change in unrealized gain on
securities, net of taxes (1,478,684) (1,478,684)
Net loss (193,851) (193,851)
Comprehensive loss
Purchase of tresury stock (7,125) (109,535) (109,535)
-----------------------------------------------------------------------------------------------
Balances, December 31, 2002 4,656,784 53,097 9,798,232 12,372,477 16,246,156 (4,923,065) 33,546,897
Change in unrealized gain on
securities, net of taxes 4,187,857 4,187,857
Net loss (1,076,189) (1,076,189)
Comprehensive income
Sale of treasury stock 2,142 3,316 27,420 30,736
Purchase of tresury stock (19,900) (272,131) (272,131)
-----------------------------------------------------------------------------------------------
Balances, December 31, 2003 4,639,026 53,097 9,801,548 16,560,334 15,169,967 (5,167,776) 36,417,170
Change in unrealized gain on
securities, net of taxes 4,492,755 4,492,755
Net loss (580,268) (580,268)
Comprehensive income
Sale of treasury stock 2,000 20,015 5,982 25,997
Purchase of tresury stock (30,200) (474,335) (474,335)
-----------------------------------------------------------------------------------------------
Balances, December 31, 2004 4,610,826 $ 53,097 $ 9,821,563 $ 21,053,089 $ 14,589,699 $(5,636,129) $ 39,881,319
===============================================================================================
Comprehensive
Income
------------------
Balances, December 31, 2001
Change in unrealized gain on
securities, net of taxes $(1,478,684)
Net loss (193,851)
-----------
Comprehensive loss $(1,672,535)
===========
Purchase of tresury stock
Balances, December 31, 2002
Change in unrealized gain on
securities, net of taxes $ 4,187,857
Net loss (1,076,189)
-----------
Comprehensive income $ 3,111,668
===========
Sale of treasury stock
Purchase of tresury stock
Balances, December 31, 2003
Change in unrealized gain on
securities, net of taxes $ 4,492,755
Net loss (580,268)
-----------
Comprehensive income $ 3,912,487
===========
Sale of treasury stock
Purchase of tresury stock
Balances, December 31, 2004
DAXOR CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
Business
Daxor Corporation is a medical device manufacturing company that offers
additional biotech services, such as cryobanking, through its wholly owned
subsidiary Scientific Medical Systems Corp. The main focus of Daxor Corporation
has been the development of an instrument that rapidly and accurately measures
human blood volume. This instrument is used in conjunction with a single use
diagnostic injection and collection kit.
Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of Daxor
Corporation and Scientific Medical Systems Corp, a wholly-owned subsidiary. All
significant inter-company transactions and balances have been eliminated in
consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosures of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.
Segment Information
The Company has one operating segment comprised of the sale of blood
volume analysis equipment and related biotech services. The Company's business
is currently conducted in the United States.
Cash and Cash Equivalents
The Company considers cash equivalents to be all highly liquid investments
purchased with an original maturity of 90 days or less.
Fair Value of Financial Instruments
Carrying amounts of certain financial instruments of the Company,
including cash and cash equivalents, accounts receivable and payable, accrued
liabilities and short term debt (loans payable and short positions on
securities) approximate fair value because of their short maturities.
Available-for-Sale Securities
Available-for-sale securities represent investments in debt and equity
securities (primarily common and preferred stock of utility companies)that
management has determined meet the definition of available-for-sale under SFAS
No. 115, Accounting for Certain Investments in Debt and Equity Securities.
Accordingly, these investments are stated at fair market value and all
unrealized holding gains or losses are recorded in the Stockholders' Equity
section of the Balance Sheet as Accumulated Other Comprehensive Income (Loss).
Conversely, all realized gains, losses and earnings are recorded in the
Statement of Operations under Other Income (Expense).
Historical cost is used by the Company to determine all gains and losses,
and fair market value is obtained by readily available market quotes on all
securities.
Accounts Receivable
Accounts receivable are deemed to be fully collectible.
Inventory
Inventory is stated at the lower of cost or market, using the first-in,
first-out method (FIFO), and consists primarily of finished goods.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets generally consist of prepayments
for future services and corporate income taxes. Prepayments are expensed when
the services are received or as the prepaid income taxes are offset by the
related income tax liability. All prepaid expenses and income taxes are expensed
within one year of the Balance Sheet date and are thus classified as Current
Assets.
Property and Equipment
Property and Equipment is stated at cost and consists of laboratory and
office equipment, furniture and fixtures, and leasehold improvements. These
assets are depreciated under the straight-line method, over their estimated
useful lives, which range from 5 to 39 years.
Amounts spent to repair or maintain these assets arising out of the normal
course of business are expensed in the period incurred. The cost of betterments
and additions are capitalized and depreciated over the life of the asset. The
cost of assets disposed of or determined to be non-revenue producing, together
with the related accumulated depreciation applicable thereto, are eliminated
from the accounts, and any gain or loss is recognized.
In accordance with SFAS No. 144, Accounting for the Impairment or Disposal
of Long-Lived Assets, management reviews long-lived assets for impairment
whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. Currently, there is no
impairment of any long-lived assets.
Revenue Recognition
The Company recognizes operational revenues from several sources. The
first source is the outright sale of equipment, the Blood Volume Analyzer, to
customers. The second source is the sale of single-use radioactive doses
(Volumex) that are injected into the patient and measured by the Blood Volume
Analyzer. The third source of revenue is service contracts on the Blood Volume
Analyzer, after it has been sold to a customer. The fourth source of revenue is
the storage fees associated with cryobanked blood and semen specimens.
The Company currently offers three different methods of purchasing the
Blood Volume Analyzer equipment. A customer may purchase the equipment directly,
lease the equipment, or rent the equipment on a month-to-month basis. The
revenues generated by a direct sale or a monthly rental are recognized as
revenue in the period in which the sale or rental occurred. If a customer is to
select the "lease" option, the Company refers its customer to a third party
finance company with which it has established a relationship, and if the lease
is approved, the Company receives 100% of the sales proceeds from the finance
company and recognizes 100% of the revenue. The finance company then deals
directly with the customer with regard to lease payments and related
collections.
The sales of the single-use radioactive doses (Volumex) that are used in
conjunction with the Blood Volume Analyzer are recognized as revenue in the
period in which the sale occurred.
When Blood Volume Analyzer equipment has been sold to a customer, the
Company offers a one year warranty on the product, which covers all mechanical
failures. This one year warranty is effective on the date of sale of the
equipment. After the one year period expires, customers may purchase a service
contract through the Company, which is usually offered in one-year increments.
These service contracts are recorded by the Company as deferred revenue and are
amortized into income in the period in which they apply. As at December 31, 2004
and 2003, deferred revenue pertaining to these service contracts was $17,465 and
$0, respectively.
The storage fees associated with the cryobanked blood and semen samples
are recognized as income in the period for which the fee applies. Although the
Company currently offers annual storage fee contracts, most customers do not pay
the annual contract fee in advance, but rather pay-as-they-go, or pay in
arrears. The amount that could be construed as "Paid in advance" is minimal and
is therefore not reclassified as deferred revenue.
Income Taxes
The Company accounts for income taxes under the provisions of SFAS No.
109, Accounting for Income Taxes. This pronouncement requires recognition of
deferred tax assets and liabilities for the estimated future tax consequences of
event attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases and
operating loss and tax credit carry forwards. Deferred tax assets and
liabilities are measured using enacted tax rates in effect for the year in which
the differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of changes in tax rates is recognized in the
statement of operations in the period in which the enactment rate changes.
Deferred tax assets and liabilities are reduced through the establishment of a
valuation allowance at such time as, based on available evidence, it is more
likely than not that the deferred tax assets will not be realized.
Comprehensive Income (Loss)
The Company reports components of comprehensive income under the
requirements of SFAS No. 130, Reporting Comprehensive Income. This statement
establishes rules for the reporting of comprehensive income and requires certain
transactions to be presented as separate components of stockholders' equity. The
Company currently reports the unrealized holding gains and losses on
available-for-sale securities, net of deferred taxes, as accumulated other
comprehensive income (loss).
Product Warrantees and Related Liabilities
The Company offers a one year warranty on the Blood Volume Analyzer
equipment. This warranty is effective on the date of sale and covers all
mechanical failures of the equipment. All major components of the equipment are
purchased and warranteed by the original 3rd party manufacturers.
Once the initial one year warranty period has expired, customers may
purchase annual service contracts for the equipment. These service contracts
warranty the mechanical failures of the equipment that are not associated with
normal wear-and-tear of the components.
To date, the Company has not experienced any major mechanical failures on
any equipment sold. In addition, the majority of the potential liability would
revert to the original manufacturer. Due to this history, a liability has not
been recorded with respect to product / warranty liability.
Stock Options
The Company applies the intrinsic-value-based method of accounting
prescribed by Accounting Principles Board, or APB, Opinion No. 25, Accounting
for Stock Issued to Employees, and related interpretations including Financial
Accounting Standards Board, or FASB, Interpretation No. 44, Accounting for
Certain Transactions involving Stock Compensation, an Interpretation of APB
Opinion No. 25, issued in March 2000, to account for its stock options. Under
this method, compensation expense is recorded on the date of the grant only if
the current market price of the underlying stock exceeded the exercise price.
SFAS No. 123, Accounting for Stock Based Compensation, established accounting
and disclosure requirements using a fair-value-based method of accounting for
stock-based employee compensation plans. As allowed by SFAS No. 123, the Company
has elected to continue to apply the intrinsic-value-based method of accounting
described above, and has adopted only the disclosure requirements of SFAS No.
123. The following table illustrates the effect on the net loss if the
fair-value-based method has been applied to all outstanding and unvested awards
in each period.
2004 2003 2002
------------ ------------ ------------
Net income (loss), as reported $ (580,268) $ (1,076,189) $ (193,851)
Deduct total stock-based employee
compensation expense determined
under fair-value-based method, net
of tax (26,229) (33,581) (71,351)
------------ ------------ ------------
Proforma net income (loss) $ (606,497) $ (1,109,770) $ (265,202)
============ ============ ============
Pro forma net income (loss) per
common share: basic and diluted $ (.13) $ (.24) $ (.06)
============ ============ ============
In 2004, a total of 25,700 stock options were issued to various employees
under the 2004 Stock Option Plan (See Note #7). No stock options were granted to
employees in 2003, and 102,000 were issued in 2002. The weighted-average fair
value per stock option granted in 2004 and 2002 was $20.10 and $15.25,
respectively. The fair value of each option grant is estimated on the date of
grant using the Black-Scholes option-pricing model with the following
weighted-average assumptions used for grants in 2004 and 2002: no dividend
yield, expected volatility of 22.74% and 40.96%, respectively, risk-free
interest rates of 1.91% and 2.13%, respectively and an expected life of 3 years
for 2004 and 2002.
Research and Development
Costs associated with the development of new products are charged to
operations as incurred.
Advertising Costs
Advertising expenditures relating to the advertising and marketing of the
Company's products and services are expensed in the period incurred.
Earnings Per Share
The Company computes earnings per share in accordance with SFAS No. 128,
Earnings Per Share. Basic earnings per common share is computed by dividing
income or loss available to common stockholders by the weighted average number
of common shares outstanding for the period. Diluted earnings per common share
is based on the average number of common shares outstanding during each period,
adjusted for the effects of outstanding stock options.
In 2004, 2003 and 2002, stock options were not included in the computation
of diluted loss per common share due to their anti-dilutive effect given the net
loss for each of those years. The number of anti-dilutive stock options excluded
from the computation of diluted loss per common share was 87,500, 62,800 and
83,800, respectively.
Leased Employees
The Company has entered into an agreement with ADP TotalSource, whereby
the Company leases its employees from ADP. The agreement requires the Company to
reimburse ADP for all employee wages, related taxes, employee benefit costs and
human resource fees.
The Company records these payments using the same classifications for
which the reimbursement is made. (i.e. Wage reimbursements are recorded as wage
expense.)
Recent Accounting Pronouncements
In December 2004, the FASB revised SFAS No. 123 (FAS 123R), Share-Based
Payment, which requires companies to expense the estimated fair value of
employee stock options and similar awards. The accounting provisions of FAS 123R
will be effective for the third quarter of fiscal 2005.
The Company will adopt the provisions of FAS 123R using a modified
prospective application. Under modified prospective application, FAS 123R, which
provides certain changes to the method for valuing stock-based compensation
among other changes, will apply to new awards and to awards that are outstanding
on the effective date and are subsequently modified or cancelled. Further
compensation expense for outstanding awards for which the requisite service had
not been rendered as of the effective date will be recognized over the remaining
service period using the compensation cost calculated for pro forma disclosure
purposes under FAS 123. The Company is in the process of determining how the new
method of valuing stock-based compensation as prescribed in FAS 123R will be
applied to valuing stock-based awards granted after the effective date and the
impact the recognition of compensation expense related to such awards will have
on its consolidated financial statements.
In November 2004, the FASB issued SFAS No. 151, Inventory Costs, an
amendment of ARB No. 43, Chapter 4. This Statement is meant to eliminate any
differences existing between the FASB standards and the standards issued by the
International Accounting Standards Board by clarifying that any abnormal idle
facility expense, freight, handling costs and spoilage be recognized as
current-period charges. This Statement is required to be adopted in the first
quarter of 2006; however, early application is permitted. The Company does not
expect the adoption of this Statement to have a material impact on results of
operations, financial position or cash flows.
In December 2003, the FASB revised FIN No. 46 (FIN 46R), Consolidation of
Variable Interest Entities, an interpretation of ARB No. 51., which requires
entities with non-similar operations to consolidate if certain factors are
present. The accounting provisions of FIN 46R became effective for periods
ending after December 15, 2003. This Interpretation did not have any impact on
results of operations, financial position or cash flows of Daxor Corporation.
Reclassifications
Certain reclassifications have been made to the Company's 2002 and 2001
consolidated financial statements to conform to the current period
presentations. Revenues, as previously presented, included dividend income,
gains on the sale of securities, and miscellaneous income. For purposes of this
financial statement presentation, these components of income have been
reclassified as Other Income.
(2) AVAILABLE-FOR-SALE SECURITIES
Upon adoption of SFAS No. 115, Accounting for Certain Investments in
Debt and Equity Securities, management has determined that the company's
portfolio is best characterized as "Available-For-Sale". SFAS No. 115 requires
these securities to be recorded at their fair market values, with the offsetting
unrealized holding gains or losses being recorded as Comprehensive Income
(Loss)in the Equity section of the Balance Sheet. The adoption of this
pronouncement has resulted in an increase in the carrying value of the company's
available-for-sale securities, as at December 31, 2004 and December 31, 2003, of
approximately 139.25% and 112.48%, respectively, over its historical cost.
In accordance with the provisions of SFAS No. 115, the adjustment in
stockholders' equity has been recorded net of the tax effect had these gains
been realized.
The Company uses the historical cost method in the determination of its
realized and unrealized gains and losses. The following tables summarize the
Company's investments as of:
December 31, 2004
Unrealized Unrealized
Type of security Cost Fair Value holding gains holding losses
- ---------------- ---- ---------- ------------- --------------
Equity 22,802,568 54,741,650 32,125,500 186,417
Debt 105,212 64,750 7,792 48,255
--------------------------------------------------------------------------
Total 22,907,780 54,806,400 32,133,292 234,672
=========== =========== =========== ===========
December 31, 2003
-----------------
Unrealized Unrealized
Type of security Cost Fair Value holding gains holding losses
- ---------------- ---- ---------- ------------- --------------
Equity $22,271,842 $47,368,871 $25,407,422 $ 310,393
Debt 35,902 30,288 2,170 7,784
--------------------------------------------------------------------------
Total $22,307,744 $47,399,159 $25,409,592 318,177
=========== =========== =========== ===========
At December 31, 2004, the securities held by the Company had a market
value of $54,806,400 and a cost basis of $22,907,780 resulting in a net
unrealized gain of $31,898,620 or 139.25% of cost.
At December 31, 2003, the securities held by the Company had a market
value of $47,399,159 and a cost basis of $22,307,744 resulting in a net
unrealized gain of $25,091,415 or 112.48% of cost.
At December 31, 2004 and December 31, 2003, marketable securities,
primarily consisting of preferred and common stocks of utility companies, are
valued at fair value. Debt securities consist of Corporate Bonds. As at December
31, 2004, two of these bonds, which have a combined cost of $56,958, are
scheduled to mature in April 2006 and May 2008. The remaining two bonds, which
have a combined cost of $48,255 are currently in default, with maturity dates
prior to December 31, 2004. Management is currently awaiting final settlement of
the bonds, and is not yet able to determine the probability of experiencing a
loss, or the amount of that loss should it occur. In accordance with SFAS No. 5,
Accounting for Contingencies, the Company has not recorded a realized loss on
these bonds. However, the Company has valued these bonds at zero and recorded an
unrealized loss of the entire cost of the bonds.
(3) PROPERTY AND EQUIPMENT
Property and equipment as at December 31, 2004 and 2003, respectively,
consist of:
2004 2003
Machinery and equipment $ 755,237 $ 727,689
Furniture and fixtures 329,050 325,635
Leasehold improvements 295,530 295,530
----------- -----------
1,379,817 1,348,854
Accumulated depreciation (1,089,245) (1,045,481)
----------- -----------
Property and equipment, net $ 290,572 $ 303,373
=========== ===========
For the years ended December 31, 2004, 2003 and 2002, depreciation expense for
the above listed assets was $43,764, $44,856 and $52,120, respectively.
(4) OTHER ASSETS
At December 31, 2003, included in Other Assets was an intangible asset
(Customer List) that was being amortized over its estimated useful life of 15
years. The asset was recorded at its original cost of $35,000 and had
accumulated amortization of $6,222 at December 31, 2003. Amortization expense
was $2,333 for the year ended December 31, 2003.
In accordance with SFAS No. 142, Goodwill and Other Intangible Assets,
management periodically reviews the asset's value for potential impairment.
As at December 31, 2004, management determined that the value of the
Customer List was impaired and accordingly, wrote off the entire net book value
of the asset. The net book value of this asset at December 31, 2003 was $28,778,
which was reclassified to amortization expense for the year ended December 31,
2004, and is included in the Depreciation and Amortization expense account.
(5) LOANS PAYABLE
As at December 31, 2004 and December 31, 2003, the Company has a note
payable of $1,500,000 and $900,000, respectively, with a bank. The note matures
each year, with an option to renew, and is classified as short term. The note
balance is an aggregate of borrowings (loans) that renews as one note each year,
but is subject to different interest rates in the initial year of borrowing,
depending on the individual amount of each borrowing and the date each borrowing
is made. Upon renewal of the note at year end, the interest rate is renewed at
the bank's prime lending rate.
The loans bear interest at approximately 3.0% at December 31, 2004 and
2003, respectively. These loans are secured by certain marketable securities of
the Company.
Short term margin debt due to brokers, secured by the Company's marketable
securities, totaled $2,613,285 at December 31, 2004 and $1,602,106 at December
31, 2003.
SHORT-TERM BORROWINGS
Years Ended December 31, 2004 and 2003
- ---------------------------------------------------------------------------------------------------------
Column A Column B Column C Column D Column E Column F
- -------- -------- -------- -------- -------- --------
- ---------------------------------------------------------------------------------------------------------
Weighted
average Maximum Average Weighted
Category of interest amount amount average
aggregate Balance at rate at end outstanding outstanding interest
short-term the end of of the during this during the rates during
borrowings period period period period the period
- ---------------------------------------------------------------------------------------------------------
2004
- ---------------------------------------------------------------------------------------------------------
Banks $1,500,000 3.00% $1,500,000 $1,449,041 3.00%
- ---------------------------------------------------------------------------------------------------------
Brokers 2,613,285 4.07% 3,058,894 2,167,566 3.56%
- ---------------------------------------------------------------------------------------------------------
All Categories $4,113,285 3.63% $4,558,894 $3,616,607 3.34%
- ---------------------------------------------------------------------------------------------------------
2003
- ---------------------------------------------------------------------------------------------------------
Banks 900,000 3.00% 900,000 883,014 3.07%
- ---------------------------------------------------------------------------------------------------------
Brokers 1,602,106 3.00% 2,345,940 1,343,335 3.87%
- ---------------------------------------------------------------------------------------------------------
All Categories $2,502,106 3.00% $3,245,940 $2,226,349 3.55%
- ---------------------------------------------------------------------------------------------------------
The average borrowings were determined on the basis of the amounts outstanding
at each month-end. The weighted interest rate during the year was computed by
dividing actual interest expense in each year by average short-term borrowings
in such year.
(6) OTHER LIABILITIES
At December 31, 2004 and December 31, 2003, the Company also maintained a
short position in certain marketable securities. These positions were sold for
$974,161 at December 31, 2004, and $663,466 at December 31, 2003, and had
respective market values of $591,483 and $547,595, resulting in unrealized gains
of $382,678 at December 31, 2004 and $115,871 at December 31, 2003.
(7) STOCK OPTIONS
In June 2004, the Company created the 2004 Stock Option Plan in an effort
to provide incentive to employees, officers, agents, consultants, and
independent contractors through proprietary interest. The Board of Directors
shall act as the Plan Administrator, and may issue these options at its
discretion. The maximum number of shares that may be issued under this Plan are
the greater of 200,000 or 5% of the Company's outstanding shares. Prior to June
2004, the Company issued options to various employees under the previous Stock
Option Plan that was also administered by the Board of Directors. All issuances
have varying vesting and expiration timelines. As at December 31, 2004 and 2003,
36,800 and 37,800 of the outstanding options were exercisable, respectively.
Details of the option activity is as follows:
Weighted
Number of Average
Shares Exercise Price
------ --------------
Outstanding, December 31, 2001 19,600 $16.10
Granted 102,000 15.25
Exercised -- --
Cancelled (62,800) 15.31
---------- ------
Outstanding, December 31, 2002 58,800 $15.47
Granted -- --
Exercised (1,000) 10.00
Cancelled (20,000) 15.20
---------- ------
Outstanding, December 31, 2003 37,800 $15.76
Granted 25,700 20.10
Exercised (1,000) 10.00
Cancelled -- --
---------- ------
Outstanding, December 31, 2004 62,500 $17.64
========== ======
Options Outstanding Options Exercisable
------------------------------------- ------------------------------------------------------------
Number Weighted-
Outstanding Average Weighted- Number Weighted-
at Remaining Average Exercisable Average
Range of December 31, Contractual Exercise December 31, Exercise
Exercise Prices 2004 Life Price 2004 Price
--------------- ---- ---- ----- ---- -----
$8.00 - $10.00 2,000 .78 years $ 10.00 2,000 $ 10.00
$14.00 - $18.00 43,800 2.81 years $ 16.32 34,800 $ 16.26
---------- ---------
$18.01 - $22.00 10,000 4.37 years $ 21.05 $
---------- ---------
$22.01 - $26.00 6,700 4.51 years $ 23.45 $
---------- ---------
62,500 3.18 years $ 17.64 36,800 $ 15.92
========== =========
In addition to the employee options described above, the Company issued 25,000
options to a consultant on March 1, 2002 at an exercise price of $21.00. These
options expire on March 1, 2005.
(8) CURRENT INCOME TAXES
The following is a reconciliation of the federal statutory tax rate of 34%
for 2004, 2003 and 2002, with the provision for income taxes:
2004 2003 2002
----- ----- -----
Statutory tax rate (34)% (34)% (34)%
Loss not subject to taxation 34% 34% 34%
----- ----- -----
Provision for income taxes 0 0 0
----- ----- -----
Effective federal tax rate 0% 0% 0%
----- ----- -----
The Company, due to current losses and loss carry forwards from previous
years, has not accrued or paid taxes based on income. It has, however, paid
State and City taxes which were assessed on its Capital Base. In accordance with
SFAS No. 109, Accounting for Income Taxes, these Capital Base assessments were
not classified as income taxes.
(9) DEFERRED INCOME TAXES
Deferred income taxes result from differences in the recognition of gains
and losses on marketable securities, as well as operating loss carry forwards,
for tax and financial statement purposes. The deferred income tax results in a
liability for the marketable securities, while the operating loss carry forwards
result in a deferred tax asset.
A valuation allowance has been recorded for the entire deferred tax asset
as a result of uncertainties regarding the realization of the asset balance due
to the history of losses and the variability of operating results.
The deferred tax liability that results from the marketable securities
does not flow through the Statement of Operations due to the classification of
the marketable securities as available-for-sale. Instead, the deferred tax
liability is recorded against the Accumulated Other Comprehensive Income, in the
Stockholders' Equity section of the Balance Sheet.
The deferred tax computations, computed at federal statutory rates of 34%,
are as follows:
2004 2003
Deferred tax assets:
Net operating loss carry forwards $ 4,907,369 $ 4,278,848
Valuation allowance (4,907,369) (4,278,848)
------------ ------------
Total deferred tax assets 0 0
============ ============
Deferred tax liabilities:
Fair market value adjustment
for available-for-sale securities $ 10,845,531 $ 8,531,081
============ ============
(9) CONCENTRATION OF CREDIT RISK
Financial instruments which potentially subject the Company to
concentrations of credit risk consist primarily of marketable securities. The
Company maintains its investments in four difference brokerage accounts, all of
which are insured by Securities Investor Protection Corporation (SIPC). The
limits of this insurance are up to $100,000 for the total amount of cash on
deposit with each Broker, and up to $500,000 for the total amount of securities
held by each Broker. Each of these brokerage houses is well known in the
industry and management does not believe that these securities bear any risk of
loss over and above the basic risk that a security bears through the normal
activity of the securities markets. However, as at December 31, 2004, the fair
market value of securities in excess of the SIPC insured limit is $53,306,400,
while there is no cash on deposit in excess of the insured limit.
(10) RELATED PARTY TRANSACTIONS
The Company subleases a portion of its New York City office space to the
President of the Company for 5 hours per week. This sublease agreement has no
formal terms and is executed on a month to month basis. The annual amount of
rental income received in each of the years ended December 31, 2004, 2003 and
2002 was $9,600.
(11) RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses were $534,615, $348,265 and $330,000 for
2004, 2003, and 2002 respectively. All research and development costs are
expensed in the period they are incurred.
(12) INTEREST EXPENSE AND INCOME
Interest expense was $111,745, $86,675 and $40,532, and interest income
was $2,795, $3,542 and $1,275 in 2004, 2003 and 2002 respectively.
(13) COMMITMENTS AND CONTINGENCIES
(A) Operating Leases
The Company leases office and laboratory space in both New York City and
Tennessee. The lease agreement for the New York City facility is a
non-cancelable lease, subject to annual increases based on the Consumer Price
Index, and will expire on December 31, 2015. The Tennessee facility is currently
leased on a month-to-month basis.
The Company subleases space in its New York facility to a related party
and a third party. Both subtenants lease on a month to month basis with no
formal agreement. The amount of rental income received for the years ended
December 31, 2004, 2003 and 2002 was $15,571 and is classified as other income
in the Statement of Operations.
Future minimum rental payments under the non-cancelable operating lease,
exclusive of future cost of living and tax escalation increases, are as follows:
2005 $262,883
2006 $262,883
2007 $262,883
2008 $262,883
2009 $262,883
Thereafter $1,577,298
Rent expense for all non-cancelable operating leases was $262, 916,
$281,506 and $239,543 for the years ended December 31, 2004, 2003 and 2002
respectively.
(B) Contingent Liabilities
The Company has pending several claims incurred in the normal course of
business, which, in the opinion of management, based on the advice of outside
legal counsel, will not have a material effect on the financial statements.
(14) SUBSEQUENT EVENTS
The Company was involved in a dispute with its landlord in New York City.
This dispute arose out of a rental rate dispute. In February 2005, the dispute
was settled and the Company voluntarily agreed to pay the landlord approximately
$45,000 in additional rent. This $45,000 liability was accrued at December 31,
2004 and 2003, and recorded in Accounts Payable and Accrues Liabilities.
(15) SELECTED FINANCIAL DATA (Unaudited)
Selected Quarterly Financial Data
Quarter Ended
-----------------------------------------------------------------
March 31 June 30 Sept 30 December 31
-----------------------------------------------------------------
2004
Total operating revenues $ 408,248 $ 254,735 $ 277,975 $ 277,448
Total revenue and other income $ 1,130,526 $ 933,239 $ 1,119,549 $ 1,047,327
Loss from operations $ (683,071) $ (927,432) $ (865,563) $ (997,487)
Net income (loss) $ 19,764 $ (261,461) $ (58,968) $ (279,603)
Net income (loss) per share $ (.00) (.06) $ (.01) $ (.06)
2003
Total operating revenues $ 218,683 $ 290,411 $ 301,816 $ 202,737
Total revenue and other income $ 737,617 $ 771,667 $ 904,183 $ 751,970
Loss from operations $ (779,012) $ (709,835) $ (757,396) $ (898,603)
Net income (loss) $ (274,585) $ (247,654) $ (180,041) $ (373,909)
Net income (loss) per share $ (.06) (.05) $ (.04) $ (.08)
Certain reclassifications have been made to the Company's 2002 consolidated
financial statements to conform to the current period presentations.
Item 9. Changes and Disagreements with Accountants on Accounting and Financial
Disclosure
There were no changes in and disagreements with accountants on accounting and
financial disclosures.
Item 9A. Controls and Procedures
Within the 90 days prior to the date of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer, Chief Financial
Officer and Controller, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures pursuant to Rule 13a-14 under the
Securities and Exchange of 1934, as amended. Based upon that evaluation, the
Chief Executive Officer, Chief Financial Officer and Controller concluded the
Company's disclosure controls and procedures are effective in timely alerting
them to material information relating to the Company required to be included in
the Company's periodic SEC filings.
There have been no significant changes in the Company's internal controls or in
other factors, which could significantly affect internal controls subsequent to
the date the Company carried out its evaluation.
Part III.
Item 10. Directors and Executive Officers of the Registrant
The information required by item 10 is incorporated by reference to our proxy
statement for our 2005 Annual Meeting of Shareholders, which will be filed with
the Securities and Exchange Commission within 120 days after the close of our
2004 year end.
Item 11. Executive Compensation
The information required by item 11 is incorporated by reference to our proxy
statement for our 2005 Annual Meeting of Shareholders, which will be filed with
the Securities and Exchange Commission within 120 days after the close of our
2004 year end.
Item 12. Security Ownership of Certain Beneficial Owners and Management Related
Shareholder Matters
This information required by item 12 is incorporated by reference to our proxy
statement for our 2005 Annual Meeting of Shareholders, which will be filed with
the Securities and Exchange Commission within 120 days after the close of our
2004 year end.
Item 13. Certain Relationships and Related Transactions
There are no relationships or related transactions beyond those which have been
disclosed in the 10-K.
Item 14. Principal Accountant Fees and Services
The information required by item 14 is incorporated by reference to our proxy
statement for our 2005 Annual Meeting of Shareholders, which will be filed with
the Securities and Exchange Commission within 120 days after the close of our
2004 year end.
Part IV
Item 15. Exhibits, Financial Statement Index and Reports on Form 8-K
(a)(1) LIST OF FINANCIAL STATEMENTS
The following financial statements are included herein under Part II, Item 8,
Financial Statements:
o Report of Independent Registered Public Accounting Firm
o Report of Independent Auditors
o Consolidated Balance Sheets - December 31, 2004 and 2003
o Consolidated Statements of Operations for the years ended December 31,
2004, 2003, and 2002
o Consolidated Statements of Stockholder's Equity and Comprehensive Income
for the years ended December 31, 2004, 2003 and 2002
o Consolidated Statement of Cash Flows for the years ended December 31,
2004, 2003 and 2002
o Notes to Consolidated Financial Statements
(3) LIST OF EXHIBITS
Description of Exhibits
31.1 Certification by Principal Executive Officer Pursuant to Securities
Exchange Act Rule 13a-14
31.2 Certification of Principal Accounting Officer Pursuant to Securities
Exchange Act Rule 13a-14
32.1 Certification by Joseph Feldschuh, MD pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification by Stephen Feldschuh pursuant to 18 U.S.C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(b) Reports on Form 8-K
There were no Reports on Form 8-K.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereto duly authorized.
DAXOR CORPORATION
by: /s/ Joseph Feldschuh
------------------------
Joseph Feldschuh, M.D
President and Principal
Executive Officer
Chairman of the Board
Dated: April 15, 2005
Pursuant to the requirements of the Securities and Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
- --------- ----- ----
/s/ Joseph Feldschuh President and Director April 15, 2005
- ------------------------ Principal Executive Officer
Joseph Feldschuh, M.D.
/s/ Stephen Feldschuh Vice President of Operations April 15, 2005
- ------------------------ & Principal Accounting Officer
Stephen Feldschuh
/s/ Gary Fischman, PhD Vice President April 15, 2005
- ------------------------
Gary Fischman, PhD
/s/ Liliya Morgaylo Corporate Treasurer April 15, 2005
- ------------------------
Liliya Morgaylo
/s/ Diane M. Meegan Corporate Secretary April 15, 2005
- ------------------------
Diane M. Meegan
/s/ Robert Willens Director April 15, 2005
- ------------------------
Robert Willens
/s/ James Lombard Director April 15, 2005
- ------------------------
James Lombard
/s/ Martin Wolpoff Director April 15, 2005
- ------------------------
Martin Wolpoff
/s/ Stephen Valentine Director April 15, 2005
- ------------------------
Stephen Valentine
Board of Directors:
Name Title
Dr. Joseph Feldschuh Chairman, President, & CEO
James Lombard Director
Martin Wolpoff Director
Robert Willens Director
Stephen Valentine Director